What the April 22 FDA Category 2 Removal Actually Means (and Doesn’t)
What the April 22 FDA Category 2 Removal Actually Means (and Doesn’t) April 21, 2026 — one day before the
The FDA Is Naming Names: Warning Letters Hit Five Research Peptide Vendors
The FDA Is Naming Names: Warning Letters Hit Five Research Peptide Vendors The agency’s crackdown on gray-market peptide suppliers is
First Head-to-Head Comparison of Semaglutide, Tirzepatide, and Retatrutide Shows Tirzepatide Leading—in Mice
First Head-to-Head Comparison of Semaglutide, Tirzepatide, and Retatrutide Shows Tirzepatide Leading—in Mice A preclinical study compared all three GLP-1 analogs
The First Large Trial Testing a GLP-1 Drug for Long COVID Just Finished Enrolling—in Under Two Months
The First Large Trial Testing a GLP-1 Drug for Long COVID Just Finished Enrolling—in Under Two Months Scripps Research’s LoCITT-T
Why GLP-1 Drugs Don’t Work the Same for Everyone: Two Studies Reveal the Genetic Divide
Why GLP-1 Drugs Don’t Work the Same for Everyone: Two Studies Reveal the Genetic Divide A Nature GWAS of 27,885
FDA to Review Seven Peptides for 503A Compounding List at July PCAC Meeting
A landmark 503A peptide review is now officially underway. The FDA announced on April 16, 2026, that its Pharmacy Compounding
GHK-Cu Is Now the Fastest-Growing Peptide in Consumer Search. The Evidence Hasn’t Caught Up.
GHK-Cu is now the fastest-growing peptide in consumer search—and the gap between interest and evidence has never been wider. Somewhere
The FDA Just Scheduled the Most Consequential Peptide Meeting in Years
The FDA peptide reclassification process took its most significant step forward on Tuesday. On Tuesday, the FDA announced it will
Retatrutide Phase 3: 28.7% Weight Loss, Osteoarthritis Relief, and a Safety Signal Worth Watching
Retatrutide just delivered Phase 3 results that redefine what’s possible in pharmaceutical weight loss—and raised new questions about tolerability. Eli
Researchers Scanned 400,000 Reddit Posts for GLP-1 Side Effects. Here’s What Doctors Are Missing.
A landmark study on GLP-1 side effects just surfaced symptoms that clinical trials may be missing. A team at the